



Esperion Therapeutics, Inc.  
 Investor Relations Department  
 3891 Ranchero Drive  
 Suite 150  
 Ann Arbor, MI 48108  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: ESPR**

Last Trade:	47.63
Trade Time:	4:00 PM ET Oct 19, 2017
Change:	-0.45 <span style="color:red">↓</span> (-0.936%)
Day Range	46.12 - 49.49
52-Week Range	9.40 - 57.40
Volume	725,691

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 10, 2017*  
[Esperion to Host Analyst and Investor Day Event on October 17](#)
- Oct 2, 2017*  
[Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid](#)
- Aug 11, 2017*  
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Aug 9, 2017*  
[Esperion Prices Public Offering of Common Stock](#)
- Aug 8, 2017*  
[Esperion Announces Proposed Public Offering of Common Stock](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 22, 2017*  
[Annual Report \(10-K\)](#)
- Mar 6, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)